scholarly journals The Effects of Boswellia serrata Gum Resin on the Blood Glucose and Lipid Profile of Diabetic Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial

2018 ◽  
Vol 23 ◽  
pp. 2515690X1877272 ◽  
Author(s):  
Saeed Mehrzadi ◽  
Bahreh Tavakolifar ◽  
Hasan Fallah Huseini ◽  
Seyed Hamdollah Mosavat ◽  
Mojtaba Heydari
Keyword(s):  
Glycosylated Hemoglobin ◽  
Lipid Lowering ◽  
Controlled Clinical Trial ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Boswellia Serrata ◽  
Double Blind ◽  
Significant Difference ◽  
To Receive

Regarding preclinical evidence for antidiabetic effects of Boswellia serrata, we evaluated antihyperglycemic and lipid-lowering effects of Boswellia serrata gum resin in type 2 diabetic patients. Fifty-six diabetic patients were randomly allocated to 2 groups to receive 250 mg of the Boswellia serrata gum resin or placebo twice daily for 8 weeks in addition to their routine antidiabetic treatments. Although there was a considerable reduction after the intervention in the field of fasting blood sugar, glycosylated hemoglobin, and triglyceride in the Boswellia serrata gum resin group, no significant difference was observed in all outcome measures between the 2 groups at the end of the study. The current study showed that 8 weeks of complementary use of Boswellia serrata gum resin with a daily dose of 500 mg had no better glucose and lipid-lowering effect than placebo in diabetic patients.

Capparis spinosa L. (Caper) fruit extract in treatment of type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial

2013 ◽  
Vol 21 (5) ◽  
pp. 447-452 ◽  
Author(s):  
Hassan Fallah Huseini ◽  
Shirin Hasani-Rnjbar ◽  
Neda Nayebi ◽  
Ramin Heshmat ◽  
Farahnaz Khaliqi Sigaroodi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Fruit Extract ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Capparis Spinosa ◽  
Type 2 Diabetic

Creatine supplementation does not augment muscle carnosine content in type 2 diabetic patients

2011 ◽  
Vol 36 (5) ◽  
pp. 764-767 ◽  
Author(s):  
Bruno Gualano ◽  
Rebeca Lugaresi ◽  
Vitor Painelli de Salles ◽  
Andréia Cristina Carrenho Queiroz ◽  
Guilherme Artioli ◽  
...  
Keyword(s):  
Creatine Supplementation ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Muscle Carnosine ◽  
1H Mrs ◽  
Double Blind ◽  
To Receive ◽  
Type 2 Diabetic ◽  
Blind Fashion

We examined whether creatine supplementation affects muscle carnosine content in type 2 diabetic patients. Subjects were randomly assigned to receive either creatine (5 g·day–1) or placebo in a double-blind fashion. At baseline and after 12 weeks, carnosine content was evaluated in gastrocnemius and soleus muscles by using a 1H-MRS technique. No changes were found in gastrocnemius (p = 0.81) and soleus (p = 0.85). We concluded that creatine supplementation does not augment muscle carnosine content in type 2 diabetic patients.

scholarly journals Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial

2021 ◽  
Author(s):  
Ling Qu ◽  
Xiaochun Liang ◽  
Guoqing Tian ◽  
Gaili Zhang ◽  
Qunli Wu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Adverse Events ◽  
Glycosylated Hemoglobin ◽  
Controlled Clinical Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Significant Difference ◽  
Acarbose Treatment

<b>OBJECTIVE </b>This study aimed to evaluate the efficacy and safety of mulberry twig alkaloids (sangzhi alkaloids, SZ-A) in the treatment of type 2 diabetes (T2D).<a></a> <p><b>RESEARCH DESIGN AND METHODS</b><b> </b><a></a>This was a multicenter, randomized, double-blind, double-dummy, and parallel controlled non-inferiority clinical trial that was conducted for 24 weeks. A total of 600 patients were randomly allocated to the SZ-A group (<i>n</i>=360) or acarbose group (<i>n</i>=240). The primary efficacy endpoint was the change of glycosylated hemoglobin (HbA<sub>1c</sub>) in comparison to baseline. In addition, adverse events (AEs), severe adverse events (SAEs), <a>treatment-related </a><a>adverse events</a> (TAEs), and gastrointestinal disorders (GDs) were monitored.</p> <p><b>RESULTS</b> After treatment for 24 weeks, the change <a>in HbA1c was −0.93% (95% CI −1.03 to −0.83) (−10.2 mmol/mol, [95% CI −11.3 to −9.1]) and −0.87% (95% CI −0.99 to −0.76) (−9.5 mmol/mol, [95% CI −10.8 to −8.3]) in the SZ-A and acarbose groups, and the least squares mean difference was −0.05% (95% CI −0.18 to 0.07) (−0.5 mmol/mol, [95% CI −2.0 to 0.8]) between the two groups with no significant difference based on covariance analysis (P > 0.05). The incidence of TAEs and GDs was significantly lower in the SZ-A group than the acarbose group (P < 0.01), but no differences were found for AEs or SAEs between two groups were observed (P > 0.05).</a></p> <p><b>CONCLUSION</b> SZ-A exhibited equivalent hypoglycemic effect to acarbose in patients with T2D. Nevertheless, the incidence of TAEs and GDs was lower following SZ-A treatment than that following acarbose treatment, suggesting good safety.</p>

scholarly journals Association of Chemerin with Complications in type 2 diabetic patients.

2019 ◽  
Vol 6 (10) ◽  
pp. 4636-4646
Author(s):  
Prinka Perswani ◽  
Rajesh Kumar ◽  
Ram Sandesh ◽  
Syeda Mehak Fatima ◽  
Syeda Moazzama Zaidi
Keyword(s):  
Pearson Correlation ◽  
Glycosylated Hemoglobin ◽  
Plasma Concentrations ◽  
Vascular Complications ◽  
Diabetic Microangiopathy ◽  
Diabetic Patients ◽  
Anthropometric Parameters ◽  
Type 2 Diabetic Patients ◽  
Significant Difference

Type 2 diabetes (T2DM) is a global epidemic and increases mortality due to its vascular complications. Chemerin has been found to exert a major role in glucose and lipid metabolism. The aim of this study was to explore the correlation between plasma Chemerin levels and microangiopathy in patients with T2DM. Methods. A total of 598 T2DM patients were classified into two groups: with and without micro vascular complications. Anthropometric parameters and blood pressure were taken. The amounts of glycosylated hemoglobin, glucose, lipid profiles, creatinine, and Chemerin concentrations in the blood were determined. The presence and severity of nephropathy, retinopathy, and neuropathy were also evaluated by specific tests. Results. Plasma levels of Chemerin in diabetic subjects with micro vascular complications were markedly elevated compared to those without. The number of micro vascular complications increased with high plasma Chemerin levels. Patients with high Chemerin levels had an increased incidence of nephropathy and retinopathy. Furthermore, the Chemerin plasma concentrations increased with the progression of diabetic nephropathy with highest values in macro albuminuria groups. In contrast, no significant difference was observed in plasma Chemerin levels between subjects with and without peripheral neuropathy. Pearson correlation analysis showed that plasma Chemerin levels were positively related to duration of diabetes, serum creatinine, and 24-hour urine albumin excretion, even after multiple adjustments. Using logistic regression analysis, plasma Chemerin concentrations were independently associated with the presence of nephropathy and retinopathy, not neuropathy. Conclusion. This study elucidated a positive correlation between increased Chemerin levels and the development of some subtypes of diabetic microangiopathy.

Sign in / Sign up

Export Citation Format

Share Document